Symbols / PMN $20.16 +11.07%
PMN Chart
About
ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates comprise of PMN310, a monoclonal antibody (mAb) for toxic oligomers for treating Alzheimer's Disease; PMN267 for treatment of amyotrophic lateral sclerosis; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils for treating multiple system atrophy. The company also develops PNM440, an alpha-synuclein vaccine for treating multiple synucleinopathies; and PMN311, an amyloid-beta vaccine for treatment of Alzheimer's. In addition, it is developing therapies for frontotemporal lobar degeneration, Huntington's disease, progressive supranuclear palsy, corticobasal degeneration, and schizophrenia. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. is headquartered in Toronto, Canada.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 43.39M |
| Enterprise Value | 27.96M | Income | -29.28M | Sales | — |
| Book/sh | 4.27 | Cash/sh | 7.17 | Dividend Yield | — |
| Payout | 0.00% | Employees | 7 | IPO | — |
| P/E | — | Forward P/E | -33.05 | PEG | — |
| P/S | — | P/B | 4.72 | P/C | — |
| EV/EBITDA | — | EV/Sales | — | Quick Ratio | 1.27 |
| Current Ratio | 1.76 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -20.00 | EPS next Y | -0.61 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2025-11-12 07:00 | ROA | -85.38% |
| ROE | -3.56% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 2.15M |
| Shs Float | 1.27M | Short Float | 5.47% | Short Ratio | 0.25 |
| Short Interest | — | 52W High | 39.75 | 52W Low | 6.27 |
| Beta | -0.40 | Avg Volume | 179.58K | Volume | 88.91K |
| Target Price | $34.42 | Recom | None | Prev Close | $18.15 |
| Price | $20.16 | Change | 11.07% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$34.43
Mean price target
2. Current target
$20.16
Latest analyst target
3. DCF / Fair value
$-99.13
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$20.16
Low
$18.20
High
$49.44
Mean
$34.43
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-06 | main | Guggenheim | Buy → Buy | $35 |
| 2025-12-01 | main | HC Wainwright & Co. | Buy → Buy | $18 |
| 2025-11-21 | reit | HC Wainwright & Co. | Buy → Buy | $4 |
| 2025-11-18 | main | Guggenheim | Buy → Buy | $5 |
| 2025-07-14 | init | HC Wainwright & Co. | — → Buy | $4 |
| 2025-05-12 | init | Maxim Group | — → Buy | $3 |
| 2025-04-01 | reit | Guggenheim | Buy → Buy | $6 |
| 2025-02-26 | reit | Guggenheim | Buy → Buy | — |
News
RSS: Latest PMN news- PMN Stock Price and Chart — NASDAQ:PMN - TradingView Fri, 27 Feb 2026 08
- $PMN stock is up 8% today. Here's what we see in our data. - Quiver Quantitative Fri, 27 Feb 2026 08
- ProMIS lines up up to $175M to extend runway into 2028, fund Alzheimer’s trial - Stock Titan Fri, 30 Jan 2026 08
- Eugene Williams Acquires 1,000 Shares of Promis Neurosciences (NASDAQ:PMN) Stock - MarketBeat Wed, 04 Mar 2026 08
- PMN Stock News Today | Earnings, Events & Price Alerts - Intellectia AI Sat, 07 Mar 2026 20
- ProMIS Neurosciences stock soars after $175 million private placement - Investing.com Fri, 30 Jan 2026 08
- ProMIS Neurosciences : PMN - 24/7 Wall St. Mon, 09 Feb 2026 08
- Abg V Siv X Ltd Net Worth (2026) - GuruFocus Mon, 16 Mar 2026 09
- ProMIS Neurosciences (PMN) director purchases 2,000 common shares in open market - Stock Titan Fri, 06 Mar 2026 12
- Promis Neurosciences (NASDAQ:PMN) Director Eugene Williams Buys 2,000 Shares - MarketBeat hu, 05 Mar 2026 02
- Ally Bridge entities disclose ProMIS (PMN) shares and warrant terms - Stock Titan Wed, 25 Feb 2026 08
- Insider Purchase: 10% owner at $PMN Buys 700,741 Shares | PMN Stock News - Quiver Quantitative Fri, 06 Feb 2026 08
- ProMIS Neurosciences (Nasdaq: PMN) names Ally Bridge's Slanix Paul Alex to board - Stock Titan Wed, 22 Oct 2025 07
- ProMIS Neurosciences Stock (PMN) Opinions on Alzheimer’s Candidate Fast Track Designation | PMN Stock News - Quiver Quantitative Mon, 06 Oct 2025 07
- Zero ARIA Cases: ProMIS's Novel Alzheimer's Drug PMN310 Advances to Final Trial Phase with Clean Safety Data - Stock Titan Wed, 03 Sep 2025 07
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 2000 | 48800.0 | — | Purchase at price 24.40 per share. | WILLIAMS EUGENE WARREN | Director | — | 2026-03-05 00:00:00 | D |
| 1 | 4000 | 92420.0 | — | Purchase at price 21.89 - 24.00 per share. | WILLIAMS EUGENE WARREN | Director | — | 2026-03-04 00:00:00 | D |
| 2 | 1629 | 25005.0 | — | Purchase at price 15.35 per share. | KAPLAN JOHANNE | Officer | — | 2026-02-19 00:00:00 | D |
| 3 | 6183 | 98310.0 | — | Stock Award(Grant) at price 15.90 per share. | WARMA NEIL K | Chief Executive Officer | — | 2026-02-03 00:00:00 | D |
| 4 | 3050 | 48495.0 | — | Stock Award(Grant) at price 15.90 per share. | KIRWIN PATRICK D | Director | — | 2026-02-03 00:00:00 | D |
| 5 | 6595 | 104860.0 | — | Stock Award(Grant) at price 15.90 per share. | MILBURY MAX A. | Officer | — | 2026-02-03 00:00:00 | D |
| 6 | 2060 | 32754.0 | — | Stock Award(Grant) at price 15.90 per share. | KAPLAN JOHANNE | Officer | — | 2026-02-03 00:00:00 | D |
| 7 | 4122 | 65540.0 | — | Stock Award(Grant) at price 15.90 per share. | CASHMAN NEIL | Officer and Director | — | 2026-02-03 00:00:00 | I |
| 8 | 700741 | 11141782.0 | — | Purchase at price 15.90 per share. | ABG MANAGEMENT, LTD. | Beneficial Owner of more than 10% of a Class of Security | — | 2026-02-03 00:00:00 | I |
| 9 | 30392 | 14929.0 | — | Purchase at price 0.49 per share. | MILBURY MAX A. | Officer | — | 2025-10-03 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 3.39M | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.15 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -19.73M | -13.86M | -23.25M | -8.23M |
| TotalUnusualItems | 22.58M | 866.74K | 5.48M | -1.10M |
| TotalUnusualItemsExcludingGoodwill | 22.58M | 866.74K | 5.48M | -1.10M |
| NetIncomeFromContinuingOperationNetMinorityInterest | 2.78M | -13.21M | -18.06M | -9.79M |
| ReconciledDepreciation | 0.00 | 21.16K | 11.22K | 45.83K |
| EBITDA | 2.86M | -12.99M | -17.77M | -9.33M |
| EBIT | 2.86M | -13.01M | -17.78M | -9.37M |
| NetInterestIncome | -76.78K | -201.39K | -282.06K | -416.29K |
| InterestExpense | 76.78K | 201.39K | 282.06K | 416.29K |
| InterestIncome | 4.73K | |||
| NormalizedIncome | -16.42M | -14.08M | -23.55M | -8.69M |
| NetIncomeFromContinuingAndDiscontinuedOperation | 2.78M | -13.21M | -18.06M | -9.79M |
| TotalExpenses | 16.83M | 14.26M | 23.38M | 8.29M |
| TotalOperatingIncomeAsReported | -16.83M | -14.26M | -23.38M | -8.29M |
| DilutedAverageShares | 1.06M | 491.71K | 300.10K | 231.42K |
| BasicAverageShares | 1.04M | 491.71K | 300.10K | 231.42K |
| DilutedEPS | 2.75 | -26.75 | -60.25 | -42.25 |
| BasicEPS | 2.75 | -26.75 | -60.25 | -42.25 |
| DilutedNIAvailtoComStockholders | 2.78M | -13.21M | -18.06M | -9.79M |
| NetIncomeCommonStockholders | 2.78M | -13.21M | -18.06M | -9.79M |
| NetIncome | 2.78M | -13.21M | -18.06M | -9.79M |
| NetIncomeIncludingNoncontrollingInterests | 2.78M | -13.21M | -18.06M | -9.79M |
| NetIncomeContinuousOperations | 2.78M | -13.21M | -18.06M | -9.79M |
| PretaxIncome | 2.78M | -13.21M | -18.06M | -9.79M |
| OtherIncomeExpense | 19.68M | 1.25M | 5.60M | -1.08M |
| OtherNonOperatingIncomeExpenses | -2.90M | 384.90K | 115.53K | 12.91K |
| SpecialIncomeCharges | 0.00 | 1.31M | 0.00 | |
| GainOnSaleOfPPE | 58.98K | |||
| OtherSpecialCharges | -1.31M | |||
| GainOnSaleOfSecurity | 22.58M | 866.74K | 4.18M | -1.10M |
| NetNonOperatingInterestIncomeExpense | -76.78K | -201.39K | -282.06K | -416.29K |
| InterestExpenseNonOperating | 76.78K | 201.39K | 282.06K | 416.29K |
| InterestIncomeNonOperating | 4.73K | |||
| OperatingIncome | -16.83M | -14.26M | -23.38M | -8.29M |
| OperatingExpense | 16.83M | 14.26M | 23.38M | 8.29M |
| ResearchAndDevelopment | 10.64M | 7.88M | 16.09M | 4.63M |
| SellingGeneralAndAdministration | 6.19M | 6.38M | 7.29M | 3.66M |
| GeneralAndAdministrativeExpense | 6.19M | 6.38M | 7.29M | 3.66M |
| OtherGandA | 6.19M | 6.38M | 7.29M | 3.66M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2023-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 1.31M | 755.41K | 343.17K | 287.82K |
| ShareIssued | 1.31M | 755.41K | 343.17K | 287.82K |
| TotalDebt | 3.91M | |||
| TangibleBookValue | 16.49M | 3.75M | -1.37M | 5.63M |
| InvestedCapital | 16.49M | 3.75M | -1.35M | 9.57M |
| WorkingCapital | 16.69M | 4.27M | 490.44K | 16.79M |
| NetTangibleAssets | 16.49M | 3.75M | -1.37M | 5.63M |
| CommonStockEquity | 16.49M | 3.75M | -1.35M | 5.66M |
| TotalCapitalization | 16.49M | 3.75M | -1.35M | 9.57M |
| TotalEquityGrossMinorityInterest | 16.49M | 3.75M | -1.35M | 5.66M |
| StockholdersEquity | 16.49M | 3.75M | -1.35M | 5.66M |
| OtherEquityInterest | 6.93M | |||
| GainsLossesNotAffectingRetainedEarnings | -371.18K | -371.18K | -195.37K | -187.92K |
| OtherEquityAdjustments | -371.18K | -371.18K | -195.37K | -187.92K |
| RetainedEarnings | -90.69M | -93.47M | -80.25M | -62.19M |
| AdditionalPaidInCapital | 107.55M | 97.59M | 79.10M | 68.04M |
| CapitalStock | 0.00 | 0.00 | 0.00 | 0.00 |
| CommonStock | 0.00 | 0.00 | 0.00 | 0.00 |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 2.42M | 9.87M | 8.27M | 12.09M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 204.85K | 516.19K | 1.86M | 11.16M |
| DerivativeProductLiabilities | 5.59K | 94.19K | 1.86M | 7.25M |
| EmployeeBenefits | 199.26K | 422.00K | 0.00 | |
| LongTermDebtAndCapitalLeaseObligation | 3.91M | |||
| LongTermDebt | 3.91M | |||
| CurrentLiabilities | 2.22M | 9.35M | 6.41M | 929.07K |
| CurrentDeferredLiabilities | 0.00 | |||
| PensionandOtherPostRetirementBenefitPlansCurrent | 38.33K | 518.70K | 0.00 | |
| PayablesAndAccruedExpenses | 2.18M | 8.83M | 6.41M | 929.07K |
| CurrentAccruedExpenses | 442.63K | 987.82K | 3.44M | 520.09K |
| InterestPayable | 0.00 | 54.40K | ||
| Payables | 1.74M | 7.84M | 2.98M | 408.98K |
| AccountsPayable | 1.74M | 7.84M | 2.98M | 408.98K |
| TotalAssets | 18.91M | 13.62M | 6.92M | 17.75M |
| TotalNonCurrentAssets | 0.00 | 0.00 | 21.16K | 32.28K |
| InvestmentsAndAdvances | 0.00 | |||
| LongTermEquityInvestment | 0.00 | |||
| InvestmentsinJointVenturesatCost | 0.00 | |||
| GoodwillAndOtherIntangibleAssets | 0.00 | 20.84K | 27.61K | |
| NetPPE | 0.00 | 321.00 | 4.67K | |
| AccumulatedDepreciation | -80.00K | -79.39K | ||
| GrossPPE | 80.32K | 84.06K | ||
| OtherProperties | 61.93K | 66.40K | ||
| MachineryFurnitureEquipment | 18.39K | 17.66K | ||
| CurrentAssets | 18.91M | 13.62M | 6.90M | 17.71M |
| OtherCurrentAssets | 47.28K | 33.22K | 4.62K | 4.39K |
| CurrentDeferredAssets | 0.00 | 195.63K | 0.00 | |
| PrepaidAssets | 5.46M | 681.15K | 920.43K | 684.24K |
| Receivables | 78.03K | 78.64K | 71.63K | 48.69K |
| OtherReceivables | 4.62K | |||
| TaxesReceivable | 20.48K | 71.63K | 48.69K | |
| AccruedInterestReceivable | 78.03K | 78.64K | 0.00 | |
| CashCashEquivalentsAndShortTermInvestments | 13.32M | 12.63M | 5.91M | 16.98M |
| OtherShortTermInvestments | 33.05K | 32.36K | 31.01K | 33.25K |
| CashAndCashEquivalents | 13.29M | 12.60M | 5.88M | 16.94M |
| CashFinancial | 13.29M | 12.60M | 5.88M | 16.94M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -27.18M | -10.84M | -17.04M | -9.31M |
| RepurchaseOfCapitalStock | -1.64M | |||
| IssuanceOfDebt | 0.00 | 6.92M | ||
| IssuanceOfCapitalStock | 27.85M | 17.75M | 4.97M | 15.87M |
| CapitalExpenditure | -1.98K | -6.04K | ||
| InterestPaidSupplementalData | 76.78K | 201.39K | 87.07K | |
| EndCashPosition | 13.29M | 12.60M | 5.88M | 16.94M |
| BeginningCashPosition | 12.60M | 5.88M | 16.94M | 806.89K |
| EffectOfExchangeRateChanges | 0.00 | -181.43K | -526.90K | -175.02K |
| ChangesInCash | 693.02K | 6.90M | -10.54M | 16.31M |
| FinancingCashFlow | 27.88M | 17.75M | 6.49M | 25.52M |
| CashFlowFromContinuingFinancingActivities | 27.88M | 17.75M | 6.49M | 25.52M |
| ProceedsFromStockOptionExercised | 28.04K | 3.60K | 1.52M | 2.74M |
| NetCommonStockIssuance | 27.85M | 17.75M | 4.97M | 15.87M |
| CommonStockPayments | -1.64M | |||
| CommonStockIssuance | 27.85M | 17.75M | 4.97M | 15.87M |
| NetIssuancePaymentsOfDebt | 0.00 | 6.92M | ||
| NetLongTermDebtIssuance | 0.00 | 6.92M | ||
| LongTermDebtIssuance | 0.00 | 6.92M | ||
| InvestingCashFlow | -693.00 | -1.35K | -1.98K | 94.62K |
| CashFlowFromContinuingInvestingActivities | -693.00 | -1.35K | -1.98K | 94.62K |
| NetOtherInvestingChanges | 2.36K | |||
| NetInvestmentPurchaseAndSale | -693.00 | -1.35K | 0.00 | -33.00 |
| SaleOfInvestment | 32.36K | 31.01K | 31.01K | 33.07K |
| PurchaseOfInvestment | -33.05K | -32.36K | -31.01K | -33.10K |
| NetBusinessPurchaseAndSale | 2.35K | |||
| SaleOfBusiness | 2.35K | |||
| NetPPEPurchaseAndSale | 0.00 | -1.98K | 92.29K | |
| SaleOfPPE | 0.00 | 98.33K | ||
| PurchaseOfPPE | 0.00 | -1.98K | -6.04K | |
| OperatingCashFlow | -27.18M | -10.84M | -17.03M | -9.31M |
| CashFlowFromContinuingOperatingActivities | -27.18M | -10.84M | -17.03M | -9.31M |
| ChangeInWorkingCapital | -11.73M | 2.94M | 5.40M | -1.56M |
| ChangeInOtherWorkingCapital | -1.40M | |||
| ChangeInPayablesAndAccruedExpense | -7.13M | 3.13M | 5.72M | 439.81K |
| ChangeInAccruedExpense | -1.03M | -1.83M | 3.05M | 471.46K |
| ChangeInPayable | -6.11M | 4.96M | 2.68M | -31.65K |
| ChangeInAccountPayable | -6.11M | 4.96M | 2.68M | -31.65K |
| ChangeInPrepaidAssets | -4.60M | -187.32K | -318.75K | -600.63K |
| ChangeInReceivables | -17.28K | |||
| OtherNonCashItems | 3.52M | 241.85K | 366.02K | |
| StockBasedCompensation | 825.81K | 271.54K | 487.63K | 515.63K |
| DepreciationAmortizationDepletion | 0.00 | 21.16K | 11.22K | 45.83K |
| DepreciationAndAmortization | 0.00 | 21.16K | 11.22K | 45.83K |
| AmortizationCashFlow | 0.00 | 20.84K | 5.07K | 5.25K |
| AmortizationOfIntangibles | 0.00 | 20.84K | 5.07K | 5.25K |
| Depreciation | 0.00 | 321.00 | 6.14K | 40.58K |
| OperatingGainsLosses | -22.58M | -868.55K | -5.11M | 1.12M |
| GainLossOnInvestmentSecurities | -22.58M | -866.74K | -4.11M | 1.10M |
| NetForeignCurrencyExchangeGainLoss | 0.00 | -1.82K | 305.41K | 85.07K |
| GainLossOnSaleOfPPE | 0.00 | -59.16K | ||
| NetIncomeFromContinuingOperations | 2.78M | -13.21M | -18.06M | -9.79M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for PMN
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|